Advertisement

Neurological Sciences

, Volume 39, Issue 12, pp 2107–2113 | Cite as

A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis

  • Hossein Pakdaman
  • Mehdi Abbasi
  • Koroush Gharagozli
  • Farzad Ashrafi
  • Hosein Delavar Kasmaei
  • Ali Amini Harandi
Original Article

Abstract

Background and aim

Interferon beta is currently the first line treatment of relapsing-remitting multiple sclerosis (RRMS). Different formulations of interferon beta are available. Avonex and CinnoVex are two interferon beta-1a being prescribed by neurologists in Iran. The aim of this study was to compare the four and half year outcome of Avonex and CinnoVex in patients with RRMS.

Methods

A total 186 of patients with definite RRMS diagnosis were followed for four and half years. Patients were randomly assigned to receive either Avonex or CinnoVex. Patients were subsequently visited every 6 months, and MRI was also undertaken prior each visit. The efficacy end points were to compare mean scores of expanded disability status scale (EDSS) and the proportion of patients with MRI and clinical activity in follow-up visits between Avonex and CinnoVex. Safety end point was to compare the percentage of adverse events between two groups.

Results

One hundred and eighty-two patients completed the study. The population of study experienced a steady increase in EDSS during follow-up with a mean increase of 1.03. Repeated measures ANOVA revealed no statistically significant difference between Avonex and CinnoVex (p = 0.78). The most common adverse events were headache, myalgia, fatigue, fever, flu symptoms, injection site pain, and depression. Direct comparison of each adverse events revealed no meaningful difference between two groups except for only a few adverse events. There was no statistically significant difference in MRI activity and clinical activity between two groups.

Conclusion

Avonex and CinnoVex showed similar efficacy and safety outcome in patients with RRMS.

Keywords

Relapsing-remitting multiple sclerosis Avonex CinnoVex Safety Iran Randomized double-blind trial 

Notes

Compliance with ethical standards

All authors declare that they have no conflict of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Trapp BD, Nave K-A (2008) Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31:247–269CrossRefPubMedGoogle Scholar
  2. 2.
    Orme M, Kerrigan J, Tyas D, Russell N, Nixon R (2007) The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 10:54–60CrossRefPubMedGoogle Scholar
  3. 3.
    Pokorski RJ (1997) Long-term survival experience of patients with multiple sclerosis. J Insur Med 29:101–106PubMedGoogle Scholar
  4. 4.
    Loma I, Heyman R (2011) Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 9:409–416CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Paty D, Li DB (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662–667CrossRefPubMedGoogle Scholar
  6. 6.
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294CrossRefPubMedGoogle Scholar
  7. 7.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna J-P, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B (2006) Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 67:944–953CrossRefPubMedGoogle Scholar
  8. 8.
    Etemadifar M, Mazdeh M, Torabi HR, Ghaffarpour M, Azimian M, Salami S, Shahkarami SMA (2010) A report of multiple sclerosis patients treated by CinnoVex™ in Iran. Tehran Univ Med J 68:30–36Google Scholar
  9. 9.
    Abolfazli R, Hosseini A, Gholami K, Javadi M, Torkamandi H, Emami S (2012) Quality of life assessment in patients with multiple sclerosis receiving interferon beta-1a: a comparative longitudinal study of Avonex and its biosimilar CinnoVex. ISRN Neurol 2012:1–6CrossRefGoogle Scholar
  10. 10.
    Goldberg L, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM (2009) Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 15:543–555PubMedGoogle Scholar
  11. 11.
    Gisela K, Alan T, Jenny B, Mia G, Jennifer E, the MSG, the European Multiple Sclerosis P (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 23:1123–1136CrossRefGoogle Scholar
  12. 12.
    Pakdaman H, Amini Harandi A, Gharagozli K, Abbasi M, Tabassi A, Ashrafi F, Ghaffarpor M, Sharifi S, Delavar Kasmae H, Assarzadegan F (2017) Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran. Int J Neurosci 127:501–507CrossRefPubMedGoogle Scholar
  13. 13.
    Najafi B, Ghaderi H, Jafari M, Najafi S, Kiadaliri AA (2015) Cost effectiveness analysis of Avonex and CinnoVex in relapsing remitting MS. Glob J Health Sci 7:139Google Scholar
  14. 14.
    Nafissi S, Azimi A, Amini-Harandi A, Salami S, Heshmat R (2012) Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial. Clin Neurol Neurosurg 114:986–989CrossRefPubMedGoogle Scholar
  15. 15.
    Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis an expanded disability status scale (EDSS). Neurology 33:1444–1452CrossRefGoogle Scholar
  17. 17.
    Sharafaddinzadeh N, Majdinasab N, Ghiasian M, Moravej-Aleali A (2011) Efficacy of interferon β1a (Cinnovex) in relapsing-remitting multiple sclerosis patients. ZJRMS 13:3–6Google Scholar
  18. 18.
    Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM (1998) Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis. Ann Neurol 43:79–87CrossRefPubMedGoogle Scholar
  19. 19.
    Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898–904CrossRefPubMedGoogle Scholar
  20. 20.
    Etemadifar M, Maghzi A, HOSSEINZADEH A (2009) Comparing side effects of cinnovex with avonex in relapsing remitting multiple sclerosis patients. JIMS 27:93–99Google Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Brain Mapping Research CenterShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations